Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

Jinyan Liu, Kara L. O’Brien, Diana M. Lynch, Nathaniel L. Simmons, Annalena La Porte, Ambryice M. Riggs, Peter Abbink, Rory T. Coffey, Lauren E. Grandpre, Michael S. Seaman, Gary Landucci, Donald N. Forthal, David C. Montefiori, Angela Carville, Keith G. Mansfield, Menzo J. Havenga, Maria G. Pau, Jaap Goudsmit and Dan H. Barouch ()
Additional contact information
Jinyan Liu: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Kara L. O’Brien: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Diana M. Lynch: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Nathaniel L. Simmons: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Annalena La Porte: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Ambryice M. Riggs: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Peter Abbink: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Rory T. Coffey: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Lauren E. Grandpre: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Michael S. Seaman: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Gary Landucci: University of California, Irvine School of Medicine, Irvine, California 92697, USA
Donald N. Forthal: University of California, Irvine School of Medicine, Irvine, California 92697, USA
David C. Montefiori: Duke University Medical Center, Durham, North Carolina 27710, USA
Angela Carville: New England Primate Research Center, Southborough, Massachusetts 01772, USA
Keith G. Mansfield: New England Primate Research Center, Southborough, Massachusetts 01772, USA
Menzo J. Havenga: TNO Biosciences, 2301 CE, Leiden, The Netherlands
Maria G. Pau: Crucell Holland BV, 2301 CA, Leiden, The Netherlands
Jaap Goudsmit: Crucell Holland BV, 2301 CA, Leiden, The Netherlands
Dan H. Barouch: Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA

Nature, 2009, vol. 457, issue 7225, 87-91

Abstract: AIDS vaccine rethink Recent setbacks have prompted a major re-evaluation of the AIDS vaccine field. One question that has been asked is whether to continue development of T-cell-based HIV-1 vaccines. Now a study of a new vaccine in monkeys challenged with simian immunodeficiency virus (SIV) suggests that the T-cell-based strategy remains potentially viable. The vaccine was prepared using two adenovirus vectors (rAd26 prime/rAd5 boost) expressing SIV Gag protein. It induced potent T-cell immune responses and some protection from infection. These findings provide pointers to the design of a new generation of T-cell-based vaccine candidates for HIV-1.

Date: 2009
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature07469 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:457:y:2009:i:7225:d:10.1038_nature07469

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature07469

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().